Vyne Therapeutics

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning

VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases

VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Drug Development Digital Event, to take place virtually June 29-July 1, 2021.

VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event

VYNE Therapeutics' (VYNE) CEO Dave Domzalski on Q1 2021 Results - Earnings Call Transcript

The drugmaker reported disappointing Q1 results.

Why VYNE Therapeutics Stock Is Crashing Today

Conference call and live webcast today at 8:30 am Eastern Time Conference call and live webcast today at 8:30 am Eastern Time

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

VYNE has two approved products and a late-stage asset.

VYNE Therapeutics: Rapidly Progressing In The Dermatology Market

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference.

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 14.00% and -12.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates

Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8:30 am Eastern Time Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8:30 am Eastern Time

VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update

BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41st Annual Health Care Conference.

VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference

Announces promising preclinical data on FMX114

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis

The stock price of VYNE Therapeutics (NASDAQ: VYNE) is trading at over 260% pre-market today as of 5:07 AM ET. This is why it happened.

VYNE Stock Price Increases Over 260% Pre-Market: Why It Happened

Harley-Davidson

Texas Instruments

Alliance Data Systems

Bridge Bancorp

Brown & Brown

Evelo Biosciences Inc

MSC Industrial Direct

Outlook Therapeutics Inc

Surgalign Holdings, Inc.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More

The stock price of Vyne Therapeutics Inc (NASDAQ: VYNE) is trading at over 10% pre-market. This is why it happened.

VYNE Stock Price Increases Over 10% Pre-Market: Why It Happened

BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of $2.37 per share.

VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update

This biotech stock is jumping, but what should investors expect from its new skincare treatments?

Can Vyne Therapeutics Stock Keep Soaring?

BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”),  today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of its common stock at a purchase price of $2.37 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about January 28, 2021, subject to the satisfaction of customary closing conditions.

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Vyne Therapeutics (VYNE) stock is taking off on Wednesday as investors take an interest in the pharmaceutical company on recent news. The post VYNE Stock: 13 Things to Know About Vyne Therapeutics as Shares Rocket Higher appeared first on InvestorPlace.

VYNE Stock: 13 Things to Know About Vyne Therapeutics as Shares Rocket Higher

The stock price of Vyne Therapeutics Inc (NASDAQ: VYNE) increased by over 70% pre-market today as of 7:06 AM ET today. This is why it happened.

VYNE Stock Price Increases Over 70% Pre-Market: Why It Happened

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (minocycline) topical foam, 4% and ZILXI ®  (minocycline) topical foam, 1.5%. AMZEEQ, the first topical minocycline to be approved by the U.S. Food and Drug Administration (“FDA”) for any condition, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults and is the first minocycline product of any form to be approved by the FDA for use in rosacea.

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

Company on track to initiate the TRILOGY Phase 3 program in 2021 Company on track to initiate the TRILOGY Phase 3 program in 2021

VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne

BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020.

VYNE Therapeutics Added to Nasdaq Biotechnology Index

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.

VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference

VYNE Therapeutics (VYNE) CEO David Domzalski on Q3 2020 Results - Earnings Call Transcript

News for Vyne Therapeutics Stock (VYNE)